{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:08:01Z","timestamp":1779084481136,"version":"3.51.4"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Venom immunotherapy (VIT) with aqueous venom extracts is a standard treatment for severe insect venom allergies. In other fields of allergen immunotherapy (AIT), depot adjuvants have been used for decades, with benefits for both safety and efficacy. Biodegradable microcrystalline tyrosine (MCT), is well-established in AIT, and has proven both safe and effective through sustained release and adjuvancy. The objective of the current study was to evaluate MCT as a depot-forming agent in VIT using a murine model of bee venom allergy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Mice were sensitised with bee venom extract and then received subcutaneous immunotherapy (SCIT) with 10, 50, or 100\u2005\u00b5g aqueous venom extracts or venom formulated with MCT or aluminium hydroxide (alum) as depot-forming agents. Systemic reactions upon VIT and challenge were assessed by measuring body temperature, while antigen-specific IgE and IgG responses were analysed by ELISA. Mast cell degranulation was evaluated by serum MCPT-1 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>VIT with MCT significantly improved survival, reduced body temperature changes, and promoted robust IgG1 and IgG2b responses. While antibody responses were comparable between MCT and alum at higher VIT doses (50 and 100\u2005\u00b5g), MCT also induced significant IgG responses at lower doses (10\u2005\u00b5g), indicating enhanced sensitivity of the immune response to MCT. MCT-treated mice further exhibited reduced mast-cell degranulation compared to untreated controls, consistent with a reduced risk of anaphylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>VIT with bee venom extract and MCT enabled safe and effective VIT by promoting protective IgG responses and reducing systemic reactions. These findings further support the evaluation of MCT as a complement to aqueous allergen extracts in VIT for human use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1840453","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:44:38Z","timestamp":1779083078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Microcrystalline tyrosine as a novel depot-forming agent in venom immunotherapy: a pre-clinical evaluation in bee-venom allergic mice"],"prefix":"10.3389","volume":"7","author":[{"given":"Marta","family":"Paolucci","sequence":"first","affiliation":[{"name":"Dept. Dermatology, University of Zurich","place":["Zurich, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Duda","sequence":"additional","affiliation":[{"name":"Dept. Dermatology, University Hospital Zurich","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"\u0160o\u0161i\u0107","sequence":"additional","affiliation":[{"name":"Dept. Dermatology, University of Zurich","place":["Zurich, Switzerland"]},{"name":"Dept. Dermatology, University Hospital Zurich","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Wallace","sequence":"additional","affiliation":[{"name":"Allergy Therapeutics plc","place":["Worthing, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J.","family":"Hewings","sequence":"additional","affiliation":[{"name":"Allergy Therapeutics plc","place":["Worthing, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray A.","family":"Skinner","sequence":"additional","affiliation":[{"name":"Allergy Therapeutics plc","place":["Worthing, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"K\u00fcndig","sequence":"additional","affiliation":[{"name":"Dept. Dermatology, University of Zurich","place":["Zurich, Switzerland"]},{"name":"Dept. Dermatology, University Hospital Zurich","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias F.","family":"Kramer","sequence":"additional","affiliation":[{"name":"Allergy Therapeutics plc","place":["Worthing, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l","family":"Johansen","sequence":"additional","affiliation":[{"name":"Dept. Dermatology, University of Zurich","place":["Zurich, Switzerland"]},{"name":"Dept. Dermatology, University Hospital Zurich","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/all.13262","article-title":"EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy","volume":"73","author":"Sturm","year":"2018","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/all.13077","article-title":"Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis","volume":"72","author":"Dhami","year":"2017","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101154","DOI":"10.1016\/j.waojou.2025.101154","article-title":"Patient preference in allergen immunotherapy - understanding the patient\u2019s view","volume":"18","author":"Becker","year":"2025","journal-title":"World Allergy Organ J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2147\/PPA.S409466","article-title":"Shared decision-making in allergen immunotherapy (AIT) options using a questionnaire for respiratory allergic patients: a delphi consensus study","volume":"17","author":"Anton","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"B5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5414\/ALX02318E","article-title":"Adherence in allergen immunotherapy: current situation and future implications","volume":"6","author":"Gehrt","year":"2022","journal-title":"Allergol Select"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/cea.14209","article-title":"Venom immunotherapy: safety and tolerability of the build-up phase with depot versus aqueous preparations","volume":"52","author":"Pravettoni","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1517\/14656566.2011.616494","article-title":"Safety of hymenoptera venom immunotherapy: a systematic review","volume":"12","author":"Incorvaia","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s40629-025-00362-8","article-title":"Non-purified\u201d hymenoptera venom extracts\u2014from protein to preferred product","volume":"35","author":"Kramer","year":"2026","journal-title":"Allergo J Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000547194","article-title":"Impact of naturally composed and size-excluded hymenoptera venom preparations on the safety and efficacy of venom immunotherapy: a monocentric experience","volume":"187","author":"Fischer","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"key":"B10","first-page":"127","article-title":"Higher frequency of early local side effects with aqueous versus depot immunotherapy for hymenoptera venom allergy","volume":"14","author":"Cadario","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.4049\/jimmunol.1800035","article-title":"Microcrystalline tyrosine and aluminum as adjuvants in allergen-specific immunotherapy protect from IgE-mediated reactivity in mouse models and act independently of inflammasome and TLR signaling","volume":"200","author":"Leuthard","year":"2018","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/all.14134","article-title":"State-of-the-art in marketed adjuvants and formulations in allergen immunotherapy: a position paper of the European academy of allergy and clinical immunology (EAACI)","volume":"75","author":"Jensen-Jarolim","year":"2020","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"114337","DOI":"10.1016\/j.ijheh.2024.114337","article-title":"Elevated aluminum excretion in patients by long-term subcutaneous immunotherapy - A cross-sectional case-control study","volume":"258","author":"Hiller","year":"2024","journal-title":"Int J Hyg Environ Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1016\/j.vaccine.2014.05.063","article-title":"Aluminium in allergen-specific subcutaneous immunotherapy\u2013a German perspective","volume":"32","author":"Kramer","year":"2014","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00105-014-2793-4","article-title":"Post-vaccination granulomas caused by delayed-type reaction to aluminum salts","volume":"65","author":"Wahl","year":"2014","journal-title":"Hautarzt"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e70181","DOI":"10.1111\/pai.70181","article-title":"Model-informed exploration of the boundaries of safe aluminium exposure from allergen immunotherapy in children","volume":"36","author":"Weisser","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1348305","DOI":"10.3389\/fimmu.2024.1348305","article-title":"Novel adjuvants in allergen-specific immunotherapy: where do we stand?","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/vaccines8020237","article-title":"Nanotechnology-based vaccines for allergen-specific immunotherapy: potentials and challenges of conventional and novel adjuvants under research","volume":"8","author":"Johnson","year":"2020","journal-title":"Vaccines"},{"key":"B19","doi-asserted-by":"publisher","first-page":"594911","DOI":"10.3389\/fimmu.2020.594911","article-title":"Shaping modern vaccines: adjuvant systems using MicroCrystalline tyrosine (MCT)","volume":"11","author":"Heath","year":"2020","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/vaccines5040032","article-title":"Microcrystalline tyrosine (MCT): a depot adjuvant in licensed allergy immunotherapy offers new opportunities in malaria","volume":"5","author":"Cabral-Miranda","year":"2017","journal-title":"Vaccines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e100115","DOI":"10.1136\/bmjos-2020-100115","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"4","author":"Percie du Sert","year":"2020","journal-title":"BMJ Open Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/cea.14279","article-title":"Strain matters in mouse models of peanut-allergic anaphylaxis: systemic IgE-dependent and ara h 2-dominant sensitization in C3H mice","volume":"53","author":"Paolucci","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1111\/all.15659","article-title":"Targeting ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice","volume":"78","author":"Paolucci","year":"2023","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12413","DOI":"10.1073\/pnas.1105695108","article-title":"Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis","volume":"108","author":"Khodoun","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1339171","DOI":"10.3389\/fimmu.2023.1339171","article-title":"Igg in the control of Fc\u03b5RI activation: a battle on multiple fronts","volume":"14","author":"Storni","year":"2023","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2249983","DOI":"10.1002\/eji.202249983","article-title":"T-cell subsets in allergy and tolerance induction","volume":"53","author":"Suhrkamp","year":"2023","journal-title":"Eur J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/all.13980","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: igG4 correlates with protection","volume":"75","author":"Jarkvist","year":"2020","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e70117","DOI":"10.1002\/eji.70117","article-title":"Insights into complex murine models of allergy and anaphylaxis: the central role of IgE and mast cells in advancing human therapies","volume":"55","author":"Nagata","year":"2025","journal-title":"Eur J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1111\/all.16491","article-title":"Six injections of modified adjuvanted PQ grass is effective and well-tolerated in a pivotal phase III trial","volume":"80","author":"Zielen","year":"2025","journal-title":"Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/ACI.0000000000000859","article-title":"Microcrystalline tyrosine-adsorbed immunotherapy","volume":"22","author":"Al Saleh","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e12037","DOI":"10.1002\/clt2.12037","article-title":"A meta-analysis on allergen-specific immunotherapy using MCT((R)) (MicroCrystalline tyrosine)-adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis","volume":"11","author":"Becker","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1111\/all.16535","article-title":"Meta-analysis of PQ grass 27600 SU efficacy and quality of life from phase III trials","volume":"80","author":"Zielen","year":"2025","journal-title":"Allergy"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1840453\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:44:39Z","timestamp":1779083079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1840453\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":34,"alternative-id":["10.3389\/falgy.2026.1840453"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1840453","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"1840453"}}